UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 29.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 42,279 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,497 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.18% of ANI Pharmaceuticals worth $3,500,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. KBC Group NV bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals during the first quarter worth about $28,000. Hantz Financial Services Inc. grew its stake in ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 249 shares during the period. Kemnay Advisory Services Inc. acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at about $48,000. Finally, State of Wyoming bought a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $50,000. 76.05% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the company. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim decreased their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a report on Wednesday. They set an “outperform” rating and a $104.00 target price on the stock. Canaccord Genuity Group cut their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Finally, Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $105.57.
ANI Pharmaceuticals Stock Performance
Shares of ANI Pharmaceuticals stock opened at $71.46 on Friday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of 15.40 and a beta of 0.45. The stock’s 50-day moving average is $77.58 and its 200-day moving average is $78.25. ANI Pharmaceuticals, Inc. has a one year low of $69.96 and a one year high of $99.39.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.ANI Pharmaceuticals’s quarterly revenue was up 25.8% on a year-over-year basis. During the same period last year, the company earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.
Insider Buying and Selling
In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 5,400 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total value of $401,220.00. Following the completion of the transaction, the chief executive officer directly owned 344,489 shares in the company, valued at $25,595,532.70. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the transaction, the senior vice president directly owned 75,534 shares in the company, valued at $5,816,118. This trade represents a 4.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 21,425 shares of company stock worth $1,687,370 in the last three months. Insiders own 8.10% of the company’s stock.
ANI Pharmaceuticals Profile
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Stories
- Five stocks we like better than ANI Pharmaceuticals
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
